Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population

Abstract Introduction In advanced non-small cell lung cancer (NSCLC), nivolumab plus ipilimumab with platinum-based chemotherapy (NIC) and pembrolizumab with platinum-based chemotherapy (PC) are commonly used treatment options. We conducted a single-center retrospective analysis comparing the two op...

Cijeli opis

Bibliografski detalji

Glavni autori:	Moritz Weber, Alexander Freiherr von Hammerstein-Equord, Manuela Weinreich, Stefan Andreas, Achim Rittmeyer
Format:	Artigo
Jezik:	Inglês
Izdano:	Springer 2026-01-01
Serija:	Cancer Immunology, Immunotherapy
Teme:	NSCLC Nivolumab Pembrolizumab Ipilimumab Germany Real-world
Online pristup:	https://doi.org/10.1007/s00262-025-04244-4
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!